Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis.

Gensler L, Inman R, Deodhar A.

Am J Med Sci. 2012 May;343(5):360-3. doi: 10.1097/MAJ.0b013e318251406c. Review.

PMID:
22543538
[PubMed - indexed for MEDLINE]
2.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
[PubMed - indexed for MEDLINE]
3.

New therapeutic approaches for spondyloarthritis.

Manadan AM, James N, Block JA.

Curr Opin Rheumatol. 2007 May;19(3):259-64. Review.

PMID:
17414952
[PubMed - indexed for MEDLINE]
4.

Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis.

Braun J, Kalden JR.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S164-7.

PMID:
19822066
[PubMed - indexed for MEDLINE]
5.

Anti-TNF-alpha therapy in ankylosing spondylitis.

De Keyser F, Van den Bosch F, Mielants H.

Cytokine. 2006 Mar 7;33(5):294-8. Epub 2006 Mar 3. Review.

PMID:
16516484
[PubMed - indexed for MEDLINE]
6.

Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies.

Freeston J, Barkham N, Hensor E, Emery P, Fraser A.

Joint Bone Spine. 2007 Mar;74(2):140-3. Epub 2007 Feb 7.

PMID:
17350312
[PubMed - indexed for MEDLINE]
7.

Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis.

Akbulut H, Koca SS, Ozgen M, Isik A.

J Rheumatol. 2010 May;37(5):1073-4. doi: 10.3899/jrheum.091469. No abstract available.

PMID:
20439531
[PubMed - indexed for MEDLINE]
8.

Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Verbruggen G, Mielants H, Veys E.

Drugs. 2004;64(24):2793-811. Review.

PMID:
15563249
[PubMed - indexed for MEDLINE]
9.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

PMID:
11986408
[PubMed - indexed for MEDLINE]
Free Article
10.

Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Haibel H, Sieper J.

Curr Opin Rheumatol. 2010 Jul;22(4):388-92. doi: 10.1097/BOR.0b013e32833aaf93. Review.

PMID:
20473176
[PubMed - indexed for MEDLINE]
11.

Management and treatment of ankylosing spondylitis.

Zochling J, Braun J.

Curr Opin Rheumatol. 2005 Jul;17(4):418-25. Review.

PMID:
15956838
[PubMed - indexed for MEDLINE]
12.

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr.

J Rheumatol. 2005 Oct;32(10):1911-7.

PMID:
16206346
[PubMed - indexed for MEDLINE]
13.

[The role of biologic agents in the therapy of ankylosing spondylitis].

Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L.

Orv Hetil. 2006 Jul 2;147(26):1203-13. Review. Hungarian.

PMID:
16898082
[PubMed - indexed for MEDLINE]
14.

[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].

Wendling D, Claudepierre P, Lohse A, Toussirot E, Breban M.

Presse Med. 2003 Oct 4;32(32):1517-24. Review. French.

PMID:
14534471
[PubMed - indexed for MEDLINE]
15.

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.

Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E.

Curr Opin Rheumatol. 2001 Jul;13(4):245-9. Review.

PMID:
11555723
[PubMed - indexed for MEDLINE]
16.

[Anti-TNF alfa therapy in ankylosing spondylitis].

Cravo AR, Tavares V, Da Silva JC.

Acta Med Port. 2006 Mar-Apr;19(2):141-50. Epub 2006 Aug 18. Review. Portuguese.

PMID:
17187716
[PubMed - indexed for MEDLINE]
Free Article
17.

[Therapeutic use of "biologics" in inflammatory joint and spinal diseases].

Seitz M.

Ther Umsch. 2002 Oct;59(10):535-43. Review. German.

PMID:
12428439
[PubMed - indexed for MEDLINE]
18.

Imaging and clinical measurements.

Pineda C, Maksymowych WP.

Am J Med Sci. 2012 May;343(5):345-9. doi: 10.1097/MAJ.0b013e3182513fb4.

PMID:
22543534
[PubMed - indexed for MEDLINE]
19.

Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.

Haraoui B, Krelenbaum M.

Semin Arthritis Rheum. 2009 Dec;39(3):176-81. doi: 10.1016/j.semarthrit.2008.06.004. Epub 2008 Aug 15.

PMID:
18706681
[PubMed - indexed for MEDLINE]
20.

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.

PMID:
16014677
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk